For Biosimilars, Profit's All In A Name

Law360, New York (June 5, 2012, 8:39 PM EDT) -- Would a drug by any other name sell as sweet? That's the big question as the U.S. Food and Drug Administration considers whether to make biosimilars take names different from their brand-name counterparts, and experts say the decision will have a big impact on the bottom lines of generics makers, brand-name drug companies and insurers. 

The success of biosimilars — and the cost savings insurers and other payors are hoping will follow — depends on how often they can be substituted for brand-name biologics. Most biosimilars will need a doctor to prescribe them specifically in place of a brand-name drug. Only...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!